Golidocitinib

Generic Name: Golidocitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁N_₉O_₂

CAS Number: 2091134-68-6

Unique Ingredient Identifier: 3BY9Z3M34G

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

Phase 2

Not yet recruiting

Conditions: Natural Killer T-cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Benmelstobart

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 47

Registration Number: NCT06733051

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

Phase 2

Not yet recruiting

Conditions: Enteropathy Associated T Cell Lymphoma

Interventions: Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
Drug: Golidocitinib

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 7

Registration Number: NCT06701344

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06630091

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Phase 2

Not yet recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Golidocitinib
Drug: Sintilimab
Drug: platinum doublet chemotherapy

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT06198907

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Go-CHOP as the Frontline Therapy for PTCL

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: CHOP Regimen

First Posted Date: 2023-07-27

Last Posted Date: 2023-09-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT05963347

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy